| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Lejoyeu. Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Alcohol and alcoholism (Oxford, Oxfordshire). vol 31 Suppl 1. 1996-11-07. PMID:8737004. |
however, at this time, the 5-ht reuptake inhibitors may be effective pharmacotherapies for alcohol-related depression. |
1996-11-07 |
2023-08-12 |
human |
| M J Owens, C A Ballenger, D L Knight, C B Nemerof. Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat. The Journal of pharmacology and experimental therapeutics. vol 278. issue 3. 1996-11-05. PMID:8819484. |
there is considerable evidence that the number of platelet 5-hydroxytryptamine (5-ht) transporter binding sites, as measured by [3h]imipramine binding, are significantly decreased, and platelet 5-ht2 receptor density is increased, in drug-free patients with major depression. |
1996-11-05 |
2023-08-12 |
rat |
| C Yang, H L Tsao, C T Chiu, L W Fan, S M Y. Regulation of 5-hydroxytryptamine-induced calcium mobilization by cAMP-elevating agents in cultured canine tracheal smooth muscle cells. Pflugers Archiv : European journal of physiology. vol 432. issue 4. 1996-10-31. PMID:8764973. |
the inhibitory effects of these agents produced both depression of the maximal response and a shift to the right of the concentration response curves of 5-ht. |
1996-10-31 |
2023-08-12 |
Not clear |
| L Arborelius, G G Nomikos, P Hertel, P Salmi, P Grillner, B B Höök, U Hacksell, T H Svensso. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn-Schmiedeberg's archives of pharmacology. vol 353. issue 6. 1996-10-29. PMID:8738296. |
since the therapeutic effect of ssris in depression has been found to be critically linked to the availability of 5-ht in brain, our experiments results support, in principle, both of the above clinically based notions. |
1996-10-29 |
2023-08-12 |
rat |
| M Hamo. [Is it feasible to develop a 5-HT basis for the treatment of depression?]. L'Encephale. vol 21 Spec No 4. 1996-10-29. PMID:8808343. |
[is it feasible to develop a 5-ht basis for the treatment of depression? |
1996-10-29 |
2023-08-12 |
Not clear |
| V Lucini, A Lucca, M Catalano, E Smerald. Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response. Journal of affective disorders. vol 36. issue 3-4. 1996-10-29. PMID:8821315. |
the molar ratio of total plasma tryptophan to the sum of other large neutral amino acids (viz., valine, isoleucine, leucine, tyrosine, phenylalanine), thought to reflect brain serotonin formation, was estimated in 69 patients with major depression before and after 1 week of treatment with different serotonin reuptake inhibitors, fluvoxamine (n = 28), fluoxetine (n = 10), citalopram (n = 7), mixed serotonin-noradrenaline reuptake inhibitor amitriptyline (n = 11), clomipramine (n = 8) and the preferentially noradrenaline reuptake inhibitor, nortriptyline (n = 5). |
1996-10-29 |
2023-08-12 |
Not clear |
| J A Carrillo, M L Dahl, J O Svensson, C Alm, I Rodríguez, L Bertilsso. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clinical pharmacology and therapeutics. vol 60. issue 2. 1996-10-29. PMID:8823236. |
fluvoxamine is a selective serotonin reuptake inhibitor used widely in the treatment of depression and other psychiatric diseases, but little is known about the specific isozymes involved in its metabolism. |
1996-10-29 |
2023-08-12 |
Not clear |
| L M Konopka, R Cooper, J W Crayto. Serotonin-induced increases in platelet cytosolic calcium concentration in depressed, schizophrenic, and substance abuse patients. Biological psychiatry. vol 39. issue 8. 1996-10-24. PMID:8731458. |
exaggerated intracellular calcium responses to challenges with serotonin (5-ht) have been reported in depression. |
1996-10-24 |
2023-08-12 |
Not clear |
| M Hamo. [New perspectives in the serotoninergic treatment for depression]. Therapie. vol 50. issue 6. 1996-10-24. PMID:8745948. |
furthermore, this neurobiological alteration very probably contributes to depression because treatments known to increase the 'serotonergic tone', such as the chronic administration of selective serotonin reuptake inhibitors (ssris), have antidepressant properties. |
1996-10-24 |
2023-08-12 |
Not clear |
| F G Graeff, F S Guimarães, T G De Andrade, J F Deaki. Role of 5-HT in stress, anxiety, and depression. Pharmacology, biochemistry, and behavior. vol 54. issue 1. 1996-10-23. PMID:8728550. |
role of 5-ht in stress, anxiety, and depression. |
1996-10-23 |
2023-08-12 |
human |
| F G Graeff, F S Guimarães, T G De Andrade, J F Deaki. Role of 5-HT in stress, anxiety, and depression. Pharmacology, biochemistry, and behavior. vol 54. issue 1. 1996-10-23. PMID:8728550. |
there are conflicting results on the function of 5-ht in anxiety and depression. |
1996-10-23 |
2023-08-12 |
human |
| W Pirker, S Asenbaum, S Kasper, H Walter, P Angelberger, G Koch, A Pozzera, L Deecke, I Podreka, T Brück. beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. Journal of neural transmission. General section. vol 100. issue 3. 1996-10-23. PMID:8748670. |
spect measurements of serotonin uptake sites in patients with depression and other psychiatric disorders might provide better insights into the pathophysiology of these disorders and into mechanisms of drug action. |
1996-10-23 |
2023-08-12 |
human |
| L Bendtsen, R Jensen, J Olese. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. Journal of neurology, neurosurgery, and psychiatry. vol 61. issue 3. 1996-10-17. PMID:8795600. |
in addition, the new selective serotonin reuptake inhibiting antidepressants, which are widely used in depression and of potential value in pain management, have never been investigated in a placebo controlled study of tension-type headache. |
1996-10-17 |
2023-08-12 |
Not clear |
| A J Cleare, A McGregor, V O'Kean. Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clinical endocrinology. vol 43. issue 6. 1996-10-15. PMID:8736274. |
neuroendocrine evidence for an association between hypothyroidism, reduced central 5-ht activity and depression. |
1996-10-15 |
2023-08-12 |
Not clear |
| A J Cleare, A McGregor, V O'Kean. Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clinical endocrinology. vol 43. issue 6. 1996-10-15. PMID:8736274. |
we tested the hypothesis that central 5-ht activity is reduced in hypothyroidism, and that this subsequently lowers the threshold for developing depression. |
1996-10-15 |
2023-08-12 |
Not clear |
| J F Deaki. Does selectivity matter? International clinical psychopharmacology. vol 11 Suppl 1. 1996-10-09. PMID:8732439. |
it is now clear that selective serotonin reuptake inhibitors (ssris) are more effective than noradrenaline reuptake inhibitors (naris) in the treatment of obsessional compulsive disorder, and obsessional features in depression predict a responsivity to ssris. |
1996-10-09 |
2023-08-12 |
human |
| H M Hochberg, D Kanter, V P House. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience. Pharmacopsychiatry. vol 28. issue 6. 1996-10-09. PMID:8773292. |
fluvoxamine, a selective serotonin reuptake inhibitor (ssri), is used to treat depression. |
1996-10-09 |
2023-08-12 |
Not clear |
| C Moret, M Brile. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. European journal of pharmacology. vol 295. issue 2-3. 1996-09-26. PMID:8720583. |
this finding suggests that a 5-ht autoreceptor antagonist or a combination of such a drug with a 5-ht uptake inhibitor would produce a greater increase of extracellular levels of 5-ht in hyposerotonergic states such as depression. |
1996-09-26 |
2023-08-12 |
rat |
| D J Goldstei. Effects of third trimester fluoxetine exposure on the newborn. Journal of clinical psychopharmacology. vol 15. issue 6. 1996-09-26. PMID:8748430. |
prospectively identified fluoxetine-exposed pregnancies were evaluated to determine whether fluoxetine, a serotonin reuptake inhibitor commonly used for the treatment of depression and obsessive-compulsive disorder, might be associated with neonatal complications after maternal fluoxetine exposure during the third trimester through delivery. |
1996-09-26 |
2023-08-12 |
Not clear |
| A J Cleare, R M Murray, V O'Kean. Reduced prolactin and cortisol responses to d-fenfluramine in depressed compared to healthy matched control subjects. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 14. issue 5. 1996-09-12. PMID:8703303. |
d-fenfluramine, a specific 5-ht releasing agent without the catecholamine effects of d,l-fenfluramine, was used as a neuroendocrine challenge in 19 subjects with major depression and 19 healthy controls. |
1996-09-12 |
2023-08-12 |
human |